Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

SC-13 is an inhibitor of flap endonuclease 1 (FEN1; IC50 = 4.2 nM) and an activator of stimulator of interferon genes (STING).1,2 It increases the levels of γ histone H2AX (γH2AX) in MCF-7 and MDA-MB-231 breast cancer cells when used at a concentration of 40 µM.1 SC13 (20 or 50 µM) induces chromosomal aberrations in MCF-7 cells. It potentiates the proliferation inhibition induced by cisplatin (Item No. 13119), 5-fluorouracil (Item No. 14416), or temozolomide (Item No. 14163) in MCF-7 cells when used at a concentration of 20 µM. SC-13 (20 µM) increases levels of cyclic GMP-AMP (cGAMP) synthase (cGAS), phosphorylated STING, chemokine (C-C motif) ligand 5 (CCL5), and CCL10 in HeLa cervical cancer and MCF-7 cells.2 In vivo, SC-13 (5 mg/kg every other day), in combination with T cells expressing chimeric antigen receptors (CARs), reduces tumor volume and weight without affecting body weight, as well as increases the number of CD8+ T cell tumor infiltrates, in a HeLa mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Targeting DNA flap endonuclease 1 to impede breast cancer progression. EBioMedicine 14, 32-43 (2016).
2. FEN1 inhibitor SC13 promotes CAR-